Healthy Volunteers
Conditions
Keywords
E2511, Healthy Participants, Elderly Participants
Brief summary
The primary objective of this study is to evaluate the safety, tolerability, and plasma pharmacokinetic (PK) of E2511 following multiple oral doses in healthy adult participants.
Interventions
DRUGE2511
E2511 tablets.
DRUGPlacebo
E2511 matched placebo tablets.
Sponsors
Eisai Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
1. Non-smoking, male, or female, non-Japanese participants age \>=18 years and \<55 years old (Cohorts 1 to 4) or age \>=55 years and \<=85 years old (Cohort 8); or Japanese participants age \>=20 years and \<55 years old (Cohorts 5 to 7) at the time of informed consent 2. Japanese participants must also satisfy the following requirements: * Must have been born in Japan of Japanese parents and Japanese grandparents * Must have lived no more than 5 years outside of Japan * Must not have changed their lifestyle or habits, including diet, while living outside of Japan 3. Weight of at least 50 kilogram (kg) and body mass index (BMI) \>=18 and \<30 kilogram per square meter (kg/m\^2) (Cohorts 1 to 7) or BMI \>=18 and \<32 kg/m\^2 (Cohort 8) at Screening
Exclusion criteria
1. Females who are breastfeeding or pregnant at Screening or Baseline 2. Females of childbearing potential who: * Within 28 days before study entry, did not use a highly effective method of contraception * Do not agree to use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation. 3. Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing 4. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism 5. Evidence of disease within 4 weeks before dosing related to chronic headaches, migraines, joint pain, or other disorders or disease resulting in chronic or intermittent pain 6. Any personal or family history of seizures (including febrile seizures) or diagnosis of epilepsy or episode of unexplained loss of consciousness 7. Any history of neurological or other medical conditions which in the opinion of the investigator has the potential to reduce seizure threshold 8. Any history of gastrointestinal surgery that may affect PK profiles of E2511, example, hepatectomy, nephrectomy, digestive organ resection at Screening 9. Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, ECG finding, or laboratory test results that require medical treatment at Screening or Baseline 10. A prolonged QT/QT interval corrected for heart rate (QTc) interval or a prolonged QT/QTc interval (QT interval corrected for heart rate using Fridericia's formula \[QTcF\] greater than \[\>\] 450 milliseconds \[ms\]). A history of risk factors for torsade de pointes 11. HR \<50 or more than 100 beats per minute at Screening or Baseline (Cohorts 1 through 7); or HR \<55 or more than 100 beats per minute at Screening or Baseline (Cohort 8) NOTE: At Baseline, HR must meet the above criteria on 3 assessments (each separated by 15 minutes) to ensure eligibility 12. Left bundle branch block 13. History of myocardial infarction or active ischemic heart disease 14. History of clinically significant arrhythmia or uncontrolled arrhythmia 15. Any lifetime history of suicidal ideation or any lifetime history of suicidal behavior as indicated by the C-SSRS 16. Any lifetime history of psychiatric disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rss: Accumulation Ratio for E2511 Based on Time and Concentration | Day 14: pre-dose up to 24 hours post-dose | — |
| Number of Participants With Clinically Significant Abnormal Vital Signs Values | From Screening up to 14 days after the last dose of study drug (up to 56 days) | — |
| Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs) Findings | From Screening up to 14 days after the last dose of study drug (up to 56 days) | — |
| Number of Participants With Clinically Significant Abnormal Ambulatory Blood Pressure | From Screening up to 14 days after the last dose of study drug (up to 56 days) | — |
| Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-suicide Severity Rating Scale (C-SSRS) | From Screening up to 14 days after the last dose of study drug (up to 56 days) | The C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior is indicated when response is yes for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation is indicated when response is yes for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. |
| Number of Participants With Clinically Significant Abnormal Physical Examination Findings | From Screening up to 14 days after the last dose of study drug (up to 56 days) | — |
| Number of Participants With Clinically Significant Abnormal Neurological Examination Findings | From Screening up to 14 days after the last dose of study drug (up to 56 days) | — |
| Number of Participants With Clinically Significant Abnormal Electroencephalogram (EEG) Findings | From Screening up to 14 days after the last dose of study drug (up to 56 days) | — |
| Cmax: Maximum Observed Plasma Concentration for E2511 | Day 1: pre-dose up to 24 hours post-dose | — |
| Css,max: Maximum Observed Plasma Concentration at Steady State for E2511 | Day 14: pre-dose up to 24 hours post-dose | — |
| tmax: Time to Reach Maximum Observed Plasma Concentration (Cmax) for E2511 | Day 1: pre-dose up to 24 hours post-dose | — |
| tss,max: Time to Reach Maximum Observed Plasma Concentration (Cmax) at Steady State for E2511 | Day 14: pre-dose up to 24 hours post-dose | — |
| Css,av: Average Steady State Plasma Concentration for E2511 | Day 14: pre-dose up to 24 hours post-dose | — |
| AUC(0-t): Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration for E2511 | Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose | — |
| AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time Zero to Infinite for E2511 | Day 1: pre-dose up to 24 hours post-dose | — |
| AUC(0-24h): Area Under the Plasma Concentration-time Curve From Time Zero to 24 hours Post-dose for E2511 | Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose | — |
| t1/2: Terminal Elimination Phase Half-life for E2511 | Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose | — |
| PTF: Peak-trough Fluctuation for E2511 | Day 14: pre-dose up to 24 hours post-dose | — |
| CL/F: Apparent Total Clearance for E2511 | Day 1: pre-dose up to 24 hours post-dose | — |
| CLss/F: Apparent Total Clearance at Steady State for E2511 | Day 14: pre-dose up to 24 hours post-dose | — |
| Vz/F: Apparent Volume of Distribution at Terminal Phase for E2511 | Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose | — |
| Rac: Accumulation Ratio for E2511 Based on Cmax and AUC | Day 14: pre-dose up to 24 hours post-dose | — |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | From Screening up to 14 days after the last dose of study drug (up to 56 days) | — |
| Number of Participants With Serious Adverse Events (SAEs) | From Screening up to 14 days after the last dose of study drug (up to 56 days) | — |
| Number of Participants With Clinically Significant Abnormal Laboratory Values | From Screening up to 14 days after the last dose of study drug (up to 56 days) | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the Concentration of Acetylcholine (ACh) in Cerebrospinal Fluid (CSF) | Baseline, Day 13 | — |
| Change From Baseline in PR Interval of the ECG (PR), QRS Interval of the ECG (QRS), and QT Interval Corrected for Heart Rate (QTc) of the ECG | Baseline up to Day 15 | — |
| Placebo Corrected Change From Baseline in HR | Baseline up to Day 15 | — |
| Placebo Corrected Change From Baseline in PR, QRS, and QTc Interval | Baseline up to Day 15 | — |
| Number of Participants With Categorical Outliers for HR, PR, QRS and QTc Interval | Baseline up to Day 15 | — |
| Number of Participants With Treatment-emergent T-wave and U-wave abnormalities | Baseline up to Day 15 | — |
| Mean Change From Baseline in 24-hours Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) up to Day 15 | Up to Day 15 | The blood pressure (BP) will be evaluated by Ambulatory Blood Pressure Monitoring (ABPM) for all participants based on the measurement of BP recordings after every 24 hours. |
| Mean Change From Baseline in Day-time, Night-time, and Hourly SBP and DBP | Baseline up to Day 15 | — |
| Mean Change From Baseline in Day-time, Night-time, and Hourly HR | Baseline up to Day 15 | — |
| Mean Change From Baseline in Day-time, Night-time, and Hourly Mean Arterial Pressure (MAP) and Pulse Pressure (PP) | Baseline up to Day 15 | — |
| Placebo Corrected Mean Change From Baseline in 24-hours SBP and DBP up to Day 15 | Up to Day 15 | The BP will be evaluated by ABPM for all participants based on the measurement of BP recordings after every 24 hours. |
| Placebo Corrected Mean Change From Baseline in Day-time, Night-time, and Hourly SBP and DBP | Baseline up to Day 15 | — |
| Placebo Corrected Mean Change From Baseline in Day-time, Night-time, and Hourly HR | Baseline up to Day 15 | — |
| Placebo Corrected Mean Change From Baseline in Day-time, Night-time, and Hourly MAP and PP | Baseline up to Day 15 | — |
| Number of Participants With Categorical Outliers for SBP and DBP | Baseline up to Day 15 | — |
| Geometric Mean Ratio of Cmax Between the Healthy Japanese and Non-japanese Participants for E2511 | Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose | — |
| Geometric Mean Ratio of AUC Between the Healthy Japanese and Non-japanese Participants for E2511 | Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose | — |
| Geometric Mean Ratio of Cmax Between the Younger Non-japanese (>=18 and <55 years) and older Non-japanese (>=55 to <=85 years) Participants for E2511 | Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose | — |
| Geometric Mean Ratio of AUC Between the Younger Non-japanese (>=18 and <55 years) and older Non-japanese (>=55 to <=85 years) Participants for E2511 | Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose | — |
| Geometric Mean Ratio Between the Non-japanese (>=18 and <55 years) and Elderly Non-japanese (>=65 to <=85 years) Participants for E2511 | Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose | — |
| Change From Baseline in Heart Rate (HR) | Baseline up to Day 15 | — |
Countries
United States
Outcome results
None listed